NCT02710669

New Formulations of Propafenone to Treat Atrial Fibrillation

Comparison of (R) and (S) Propafenone for Prevention of Atrial Fibrillation Induction

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 193 (actual)
• Sponsor: Vanderbilt University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Propafenone is a currently used medicine to treat atrial fibrillation and is a mixture of two compounds, (R)-propafenone and (S)-propafenone. In this study, the investigators will randomize participants to (R)-propafenone, (S)-propafenone, or placebo.

Detailed description

Atrial fibrillation is a common cardiac arrhythmia that needs development of more effective medications. Propafenone is a medicine currently used to treat atrial fibrillation and is a mixture of two compounds, (R)-propafenone and (S)-propafenone. The investigators have discovered that purified (R)-propafenone may be more effective than (S)-propafenone for treatment of atrial fibrillation, and that (S)-propafenone reduces the efficacy of (R)-propafenone when administered as a mixture. This study will compare the ability of (R)-propafenone, (S)-propafenone, and placebo to suppress the induction of atrial fibrillation in participants undergoing an atrial fibrillation ablation procedure.

Conditions

• Atrial Fibrillation

Interventions

Type	Name	Description
DRUG	(R)-propafenone
DRUG	(S)-Propafenone
DRUG	Placebo

Timeline

• Start date: 2016-10-01
• Primary completion: 2020-03-11
• Completion: 2020-04-01
• First posted: 2016-03-17
• Last updated: 2022-06-03
• Results posted: 2021-05-14

Locations

1 site across 1 country: United States